Recent Advances in Pharmacotherapy of

CCFDr Ketan Asawalle

JR3 Dept of PharmacologySVNGMC Yavatmal

Scope of Presentation

• Definition

• Epidemiology• Classification of Heart

Failure• Etiology and

Pathophysiology• Signs and Symptoms

• Management

• Summary

• Conclusion

Heart Failure• A pathophysiologic state in which an abnormality of cardiac function is

responsible for failure of the heart to pump blood at a rate commensurate with metabolic requirements of the tissues -E Braunwald.

• Heart Failure is a clinical syndrome which occurs because of an inherited of acquired abnormality of

1.Cardiac Structure. 2. Cardiac Function.

Developing a constellation of

1. Clinical Symptoms - dyspnoea and fatigue.

2. Signa - edema and rales.

that lead to frequent hospitalizations, a poor quality of life, and a shortened life expectancy- Harrison’s princilple of internal medicine 18th ed.

Epidemiology• Prevalence - 2% in developing countries.

• More than 20 million people affected worldwide.

• Affects 10% of people over 65 year.

• It is the most common condition for which patients 65 + require admission to hospitals.

• Affects over 50% of people with 85+ years.

• Approx 10% of patients with HF die each year.

• Prevalance in india- 1.87 %

Classification• BY EJECTION FRACTION

• Reduced ejection fraction(<40-50%)- systolic heart failure

• Preserved ejection fraction(>40-50%)- diastolic heart failure

• BY TIME COURSE

• Chronic heart failure(CHF)

• Acute heart failure (Cardiogenic Shock)

• ANATOMICALLY

• Left sided- LHF

• Right sided- RHF(CHF)

• BY OUTPUT

• High output failure-Thyrotoxicosis, Paget's dis, Anemia, Pregnancy, A-V fistula

• Low output failure – 95% of HF is this

Etiology• Reduced ejection fraction(< 50%)

• Condition that leads to an alteration in LV structure or function can predispose a patient to developing HF.

• Coronary artery disease - MI, Angina (60- 70 %)

• Chronic pressure overload disease - Hypertension( 75%), valvular disease

• Chronic volume overload- intracardiac and extracardiac shunting

• Non ischaemic cardiomyopathy

• Drug induced damage- metabolic disorder

• Disorders of rate and rhythm

• Preserved ejection fraction(> 50%)

• Pathologic hypertrophy

• Restrictive cardiomyopathy

• Fibrosis

• Aging

• Pulmonary heart disease - Cor pulmonale, pulmonary vascular dis

• High output states- metabolic disorders, anemia, systemic AV shunting

RISK FACTORS

SIGNS and SYMPTOMS

Management of CCF

Non Pharmacological• Activity-

• Routine modest exercise for class I-III

• For eu-volemic patients- regular isotonic exercise such as walking or riding a stationary bicycle ergometer

• Diet-

• Restriction of sodium (2-3 g daily) is recommended in all patients, Extra < 2g reduction in moderate to severe cases.

• Fluid restriction (<2 L/day) if hyponatremia (<130 meq/L)

• Caloric supplementation- with advanced HF and unintentional weight loss or muscle wasting (cardiac cachexia)

Pharmacological measures

DRUGS FOR ACUTE DECOMPENSATED HF

• DIURETICS- Furosemide /hydrochlorthiazide

• VASODILATORS- Nitroprusside, Nitroglycerin, Nesiritide

• INOTROPIC AGENTS- dobutamine, dopamine, milrinone, levosimendan

Drug Therapy for Chronic HF Due to Systolic Dysfunction

DIURETICS-furosemide / hydrochlorthiazide

ACE-INHIBITORS*-captopril• ARBs*- losartan• HYDRALAZINE + ISOSORBIDE*-when ACE-I or ARB contraindicated or not fully effective

• BETA BLOCKERS*• SPIRONOLACTONE*• DIGOXIN* = SURVIVAL BENEFIT

Surgical measures

• Cardiac Re-synchronization

• Implantable Cardiac Defibrillators

• Intra-aortic balloon counter pulsation

• Percutaneous and surgically implanted LV assist devices

• Cardiac transplantation

Mechanism of Action of Drugs

Used in CCF

Diuretics• High ceiling diuretics (furosemide, bumetanide) are the diuretics of choice for mobilizing edema fluid.• In advanced CHF after chronic use, resistance may develop.• Addition of a thiazide/ metolazone/spironolactone to furosemide may overcome the resistance. • Diuretics: (a) Decrease preload and improve ventricular efficiency by reducing circulating volume.(b) Remove peripheral edema and pulmonary congestion. • Used in combination with venodilators.• Diuretics have no role in asymptomatic left ventricular dysfunction, and brisk diuresis can worsen some cases.• They do not influence the disease process in CHF. • Diuretics may cause activation of RAS (if hypovolemia occurs) which has adverse cardiovascular consequences.• Chronic diuretic therapy tends to cause hypokalaemia, alkalosis and carbohydrate intolerance.

Renin Angiotensin system (RAS) Inhibitors

• ACE inhibitors and ARBs are used to block RAS.

• They afford symptomatic as well as disease modifying benefits in CHF by causing vasodilatation, retarding/preventing ventricular hypertrophy, myocardial cell apoptosis, fibrosis intercellular matrix changes and re-modeling

• ACE inhibitors raise the level of kinins which stimulate generation of cardioprotective NO and PGs

• They are thus recommended for all grades of CHF, unless contraindicated, or if renal function deteriorates.

• ACE inhibitor therapy is generally started at low doses which are gradually increased.

Vasodilators• First used i.v. to treat acute heart failure that occurs in advanced cases or following

MI, • Their use by oral route has been extended to long-term therapy of chronic CHF • Preload Reduction

- Nitrates cause pooling of blood in systemic capacitance vessels to reduce ventricular end-diastolic pressure and volume

- It is indicated when the central venous pressure (CVP) is raised and in dilated cardiomyopathy.

- However, lowering of preload (by vasodilators + strong diuretics) beyond a limit may reduce output of a failing heart

- Occurrence of nitrate tolerance limits their utility in routine treatment of CHF • After load reduction

- Hydralazine dilates resistance vessels and reduces aortic impedance so that even weaker ventricular contraction is able to pump more blood

- Systolic wall stress is reduced. - It is effective in forward failure when cardiac index (CI = min output/body surface

area) is low (< 2.5 L/min/m2) without a marked increase in CVP (< 18 mm Hg). - Marked tachycardia, worsening of myocardial ischaemia and fluid retention limit

long-term use of hydralazine monotherapy.

Vasodilators• Pre- and After load reduction

- Sodium nitroprusside is a high efficacy i.v. dilator with equal action on the two types of vessels.

- reduces ventricular filling pressure as well as systemic vascular resistance.

- Cardiac output and renal blood flow are increased

- employed in conjunction with a loop diuretic + i.v. inotropic drug to tide over crisis in severely decompensated patients.

• When Hydrazine and Nitrates are combined they supplement each other and nitrate tolerance is attenuated by Hydralazine

• Severe CHF patients already receiving ACE inhibitors + digoxin + diuretic have obtained extra benefit from addition of hydralazine with or without a nitrate.

ß-Adrenergic Blockers• Metoprolol, Bisoprolol, Nebivolol and the nonselective β + selective α1

blocker Carvedilol in mild to moderate CHF treated with ACE inhibitor ± diuretic, digitalis.

• A large number of randomized trials including

- Metoprolol in dilated cardiomyopathy trial (1993),

- US carvedilol trial (1996), MERIT-HF trial (1999), CIBIS-II trial (1999),

- CAPRICORN trial (2001),

- COPERNICUS trial (2002)

have demonstrated subjective, objective, prognostic and mortality benefits of the above named β blockers over and above that afforded by ACE inhibitors + diuretic ± digitalis.

ß-Adrenergic Blockers• Immediate hemodynamic action of β blockers is to depress cardiac

contractility and ejection fraction, these parameters gradually improve over weeks.

• The benefits appear to be due to antagonism of

- ventricular wall stress enhancing,

- apoptosis promoting and

- pathological remodeling effects

of excess sympathetic activity (occurring reflexly) in CHF, as well as due to prevention of sinister arrhythmias.

• Lower plasma markers of activation of sympathetic, renin-angiotensin systems and endothelin-1

ß-Adrenergic Blockers• Greatest utility of β blockers has been shown in mild to moderate

(NYHA class II, III) cases of dilated cardiomyopathy with systolic dysfunction

• Encouraging results (upto 35% decrease in mortality) have been obtained in class IV cases as well

• There is no place for β blockers in decompensated patients.

• Starting dose should be very low—then titrated upward as tolerated to the target level (carvedilol 50 mg/day, bisoprolol 10 mg/day, metoprolol 200 mg/day).

• A long-acting preparation (e.g. sustained release metoprolol) or 2–3 times daily dosing to produce round-the-clock β blockade should be selected.

Aldosterone Antagonists

Fibroblast proliferation and fibrotic change in myocardium → worsening systolic dysfunction and pathological remodeling.

Expansion of e.c.f. volume → increased cardiac preload.

Hypokalemia and hypomagnesemia → increased risk of ventricular arrhythmias and sudden cardiac death.

Enhancement of cardiotoxic and remodeling effect of sympathetic overactivity. SPIRONOLACTONE, EPLERINONE

Aldosterone Antagonists• It is indicated as add-on therapy to ACE inhibitors + other drugs in

moderate-to-severe CHF.

• It can retard disease progression, reduce episodes of decompensation and death due to heart failure as well as sudden cardiac deaths, over and above the protection afforded by ACE inhibitors/ARBs ± β blockers.

• Only low doses (12.5–25 mg/day) of spironolactone should be used to avoid hyperkalaemia; particularly because of concurrent ACE inhibitor/ARB therapy.

• It may help restoration of diuretic response to furosemide when refractoriness has developed. .

• The onset of benefit of aldosterone antagonist in CHF is slow.

• It is contraindicated in renal insufficiency because of risk of hyperkalemia— requires serum K+ monitoring.

SYMPATHOMIMETIC INOTROPIC DRUGS

• Drugs with β1 adrenergic and dopaminergic D1 agonistic actions have positive inotropic and vasodilator properties.

• Dobutamine (2–8 μg/kg/min) a relatively selective β1 agonist with prominent inotropic action is the preferred drug for i.v. infusion in acute heart failure accompanying myocardial infarction (MI), cardiac surgery as well as to tide over crisis in advanced decompensated CHF.

• Dopamine (3–10 μg/kg/min by i.v. infusion) has been used in cardiogenic shock due to MI and other causes.

• Low rates of dopamine infusion (~2 μg/kg/min) cause selective renal vasodilatation (D1 agonistic action) which improves renal perfusion and g.f.r.

• Development of tolerance and cardiotoxic potential when used regularly.

Phosphodiesterase 3 Inhibitors

Inamrinone (amrinone)

• Bipyridine derivative is a selective phosphodiesterase 3 (PDE3) inhibitor.

• Specific for intracellular degradation of cAMP in heart, blood vessels and bronchial smooth muscles.

• Amrinone increases myocardial cAMP and transmembrane influx of Ca2+.

• It does not inhibit Na+K+ATPase, and its action is independent of tissue catecholamines as well as adrenergic receptors.

• The two most important actions of amrinone are positive inotropy and direct vasodilatation: has been called an ‘inodilator’

• Both preload and after load are reduced

Phosphodiesterase 3 Inhibitors• In CHF patients i.v. amrinone action starts in 5 min and lasts 2–3 hours;

elimination t1⁄2 is 2–4 hours.

• Adverse effects - Thrombocytopenia is the most prominent and dose related side effect,

• It is indicated only for short-term i.v. use in severe and refractory CHF, as an additional drug to conventional therapy with digitalis, diuretics and vasodilators.

• Dose: 0.5 mg/kg bolus injection followed by 5–10 μg/kg/ min i.v. infusion (max. 10 mg/kg in 24 hours).

• Milrinone

Related to inamrinone, it has similar action but is more selective for PDE3, and is at least 10 times more potent. It is shorter-acting with a t1⁄2 of 40–80 min.

Nesiritide

• This recombinant brain natriuretic peptide (BNP) has been approved for i.v. use to relieve dyspnoea and other symptoms in refractory CHF.

• It enhances salt and water excretion and is a potent vasodilator with profile of action similar to i.v. glyceryl trinitrate;

• Reduces ventricular filling pressure.

• Additional haemodynamic and symptomatic improvement can be obtained for short periods, but no long term benefits are evident in CHF.

Tolvaptan

• This is an orally active nonpeptide vasopressin V2 receptor antagonist introduced recently for the correction of water retention and hyponatremia occurring in ‘syndrome of inappropriate ADH secretion’ (SIADH) as well as in advanced CHF.

• Tolvaptan has afforded short-term improvement by increasing water excretion, restoring serum Na+ and relieving dyspnoea.

• However, no long-term benefits have been noted.

Medicines used in the first line management of heart failure

DRUG CLASS DOSE REGIME SIDE EFFECTS

ACEIsRamiprilPerindoprilLisinoprilEnalaprilCaptopril

1.25 – 10mg daily (2 divided doses)2.5 – 5mg daily2.5 – 35mg daily2.5mg daily – 10-20mg twice daily6.25 – 50mg three times daily

Postural hypotension; dry cough; ↑ plasma K+;caution with renal dysfunction. Rarely angio-oedema.Not to be used during pregnancy

β-blockersBisoprololNebivololCarvedilol

1.25 – 10mg daily1.25 – 10mg daily3.125 – 25mg twice daily

Bradycardia; worsening of heart failure; hypotension;fatigue; GI disturbances; cold extremities

Diuretics:FurosemideBumetanideBendroflumethiazide

20 – 40mg once or twice daily0.5 - 2mg daily 2.5mg daily – 10mg daily

Loop diuretics: ↓ K+ and ↓ Na+ ; hypovolaemia;hypotension; ↑ creatinine; ↑ risk of goutThiazides: ↓ K+ ; ↑ risk of gout; ↑ riskof diabetes mellitus. Rarely ↓ Na+

Medicines used in the second-line management of heart failure

DRUG CLASS DOSE REGIME CLASS SIDE EFFECTS

ARBsValsartanLosartanCandesartan

40-160mg twice daily12.5 – 150mg daily4 – 32mg daily

Postural hypotension; ↑ plasma K+; caution with renal dysfunction.Not to be used during pregnancy

Aldosterone(mineralocorticoidreceptor) AntagonistsSpironolactoneEplerenone

12.5 – 50mg+ daily25 – 50mg daily

↑ plasma K+ - discontinue if K+ levels > 5mmol/L; caution with↓ renal function.Gynaecomastia (with spironolactone).Do not use eplerenone with strong inhibitors of CYP 3A4

Other drugs which can be used in HF-INOTROPIC AGENTS- Cardiac Glycosides, Phosphodiesterase inhibitors, dopamine receptor agonists IvabradinAnticoagulantsAntiarrhythmic agents

Pathophysiology and Pharmacotherapy in CCF

Reduced CardiacOutput

Compensatorymechanisms

Symp. stimulationRAS activation

Increased systemicvascular resistance

Increased impedanceto ventricular outflow

Myocardialinadequacy

VolumeExpansion

Increasedstroke volume

initially

VentricularDilatation

VentricularRemodelling

Aldosterone

Venodilators Diuretics

Digitalis

ArteriolarDilators Spironolactone

ACEIß B

Diagnosis• Detailed history, clinical examination, ECHO and/or serum natriuretic peptide levels• Confirm heart failure and Assess the severity of symptoms

Treatment• Education on lifestyle management and exercise training

Step- 1• ACE inhibitor (or ARB if ACEI not tolerated) +/- β-blocker**• Concomitant therapy with β-blocker + Diuretic (or ARB if ACEI not tolerated)• If still symptomatic with optimised triple therapy (ACEI, β-blocker, diuretic)

Step- 2• ADD mineralocorticoid receptor antagonist (MRA) (ARB may be considered if MRA not suitable)• hydralazine + isosorbide may be useful in black populations / patients not responding or intolerant of

step 2 combinations

Step- 3• Consider adding in digoxin / ivabradine / use of non-surgical interventional therapies (ICD, CRT)

Current trend of drugs used in CCf according to the grade of Heart failure

NEED FOR NEWER THERAPIES

• Available drugs treat only symptomatically

• Even the available drugs do not control symptoms effectively

• Associated side effects are more

• Needed life long treatment

• HF is associated with high morbidity and mortality

Novel Agents n CCF• Newer Inotropes-

• Cardiac myosin activators- Omecamtive mecarbil• Na/K-ATPase inhibitors- Istaroxime• Ryanodine receptor stabilizers- JTV-519(K 201),S107,S44121• SERCA2a activators- MYDICAR

• Vasodilators- Relaxin• Neuregulins-

• recombinant human NRG-1β2 • Novel RAAS blockers-

• Direct renin inhibitors- Oral Aliskiren,IV Remikiren, IV Enalkiren

• Angiotensin receptor & neprilysin inhibitors- LCZ696, AHU377 ,Candoxatril, Ecadotril

• Aldosterone blockers- • Non steroidal minrelocorticoid receptor antagonist-

PF3882845,BR-4628 • Aldosterone synthase inhibitors- FAD286, LCI699

• Dual ACE/NEP Inhibition – Vasopeptidase Inhibitors• Omapatrilat, sampatrilat, fasidotrilat, MDL 100240, Z13752A, BMS

189921 and mixanpril• Dual NEP & ECE(endothelin converting enz.) inhibitors

• GGS34043, GGS34226, GGS26303, SLV306• Triple enzyme inhibitors of ECE/NEP/ACE

• GGS26670 • Dual dopamine D2-α2 agonist

• Nolomirol • Dopamine β-Hydroxylase inhibitor

• Nepicastat• Adenosine A1 receptor antagonists

• BG9719,BG9928• Carnitine palmitoyl transferase-1(CPT-1) inhibitors

• Etoxomir, Oxenicine• Matrix Metalloproteinase (MMP) Inhibitors

• Batimastat, ilomastat, marimastat and prinomastat• Immune modulator

• CelacadeTM

Newer Inotropic Agents

• Cardiac myosin activators- Omecamtive mecarbil

• Na/K-ATPase inhibitors- Istaroxime

• Ryanodine receptor stabilizers- JTV-519(K 201),S107,S44121

• SERCA2a activators- MYDICAR

Cardiac Myosin Activators- Omecamtive mecarbil (Phase II b)

Previously referred to as CK-1827452

Cardiac-specific myosin activator.

Studied for a potential role in the treatment of left ventricular systolic heart failure.

Targets and activates myocardial ATPase and improves energy utilization.

Enhances effective myosin cross-bridge formation and duration, while the velocity of contraction remains the same.

It also increases the rate of phosphate release from myosin, thereby accelerating the rate-determining step of the cross-bridge cycle.

Disadvantage :As it prolongs systole, shorten diastole- inadequate coronary flow & ventricular filling so lowers threshold for myocardial ischemia in patients with CAD

Cardiac Myosin Activators- Omecamtive mecarbil

• MOA:

accelerate transition of actin-myosin complex from a weakly bound to strongly bound configuration

↓

↑ myosin head interaction with actin

↓ nonproductive ATP hydrolysis

↓

↑duration of systole

↑stroke volume

improvement in myocardial systolic function in absence of arrythmogenesis & ↑ O2 consumption

Na/K-ATPase inhibitors - Istaroxime ( Phase II)• MOA-

• Inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase).

• Stimulation of the sarcoplasmic endoplasmic reticulum calcium ATPase(SERCA) isoform 2 (SERCA2) – Lucitropic action

• Enhances the heart’s relaxation phase, protects from arrhythmogenesis caused by calcium overload

• Significantly reducing PCWP.

• Improves ejection fraction, stroke volume and systolic blood pressure, while also enhancing ventricular filling.

• Reduces heart rate and ventricular diastolic stiffness

• Wider margin of safety

Ryanodine receptor stabilizers (JTV519 )• Ca+2 entry in SR triggers further its release via activating the ryanodine

receptor 2 (RyR2)

• Diastolic Ca2+ leak through dysfunctional RyR2, leak may lead to a reduction in SR Ca2+ content, with less Ca2+ available for release and consequently weaker muscle contractions.

• Calstabin proteins increase the probability of the channel to be in its closed state, RyR channel stabilizers.

• MOA- JTV519 (originally called K201), S107, S44121 enhances RyR-calstabin binding and stabilizes the closed state of the RyR thus preventing SR Ca2+ leak

• Preserve left ventricular systolic and diastolic function

• Prevents left ventricular remodeling

SERCA 2a activators - MYDICAR (Phase III)

• SERCA2a mediates the reuptake of Ca2+ back into the SR during the early diastolic phase .

• Adeno-associated virus 1 (AAV1) is used for delivery of SERCA2a complementary DNA by intracoronary infusion in trials.

• Improved systolic and diastolic functions, improved ventricular metabolic reserve, and reducing the likelihood of ventricular arrhythmias during ischemia-induced Ca2+ overload

• Drawbacks- inhomogeneous SERCA2 overexpression may be pro-arrhythmic , implantation of a cardioverter defibrillator was an inclusion criterion for the trial.

Vasodilators• Relaxin• Serelaxin

Vasodilators - Serelaxin (Phase III)

• Recombinant human relaxin- 2

• Relaxin- circulating peptide found in pregnant women

• Regulates systemic vasodilation

• The rapid vasodilatory responses of relaxin are mediated by activation of endothelial NOS.

• Reduces pulmonary capillary wedge pressure and systemic vascular resistance

• Improves dyspnea significantly

• Reduces hospital stay with HF

• Dose 30 μg/kg/day infusion

Neuregulins• Recombinant human NRG-

1β2.

Neuregulins - Recombinant human NRG - 1ß2 (Phase III)• Growth-promoting proteins of the epidermal growth factor family .

• Neuregulin-1 (NRG-1) plays a key role in cardiac chamber differentiation and trabeculation in the developing embryo and in cardiac function.

• Act through the ErbB family of tyrosine kinase receptors.

• In the later stages of HF, both NRG-1 expression and NRG-1/ErbB signaling are inhibited, enhanced susceptibility of cardiomyocytes to cell death and progression of HF.

• Recombinant human NRG-1β2 infusion improve cardiac structure and function by 90 days

• Increase in cardiac output as well as vasodilator effect.

• Drawbacks- potential for acceleration of tumor growth , administered intravenously over many hours on a daily basis, thus limiting its utility in chronic HF , Nausea

Novel blockers of

RAS• Direct renin inhibitors- Oral Aliskiren,IV

Remikiren, IV Enalkiren• Angiotensin receptor & neprilysin

inhibitors- LCZ696, AHU377 ,Candoxatril, Ecadotril

• Aldosterone blockers- • Non steroidal minrelocorticoid receptor

antagonist-PF3882845,BR-4628 • Aldosterone synthase inhibitors-

FAD286, LCI699

RAS

Direct renin inhibitors - Oral Aliskiren,IV Remikiren, IV Enalkiren

• Reduce increased plasma renin activity directly

• Independent of plasma levels of BNP, background effect of beta blockers & ACEI.

• MOA- inhibit conversion of Angiotensinogen to angiotensin-I

• Reduces systemic vascular resistance & PCWP

• Ventricular remodeling significantly attenuated

• Delays cardiovascular death and hospitalization

• Drawback- hyperkalemia, hypotension

Angiotensin receptor and neprilysin inhibitors -• Candoxatril, Ecadotril• LCZ696 (Angiotensin receptor blocker)• AHU377 moiety (neprilysin inhibitor)• Phase II

• Atrial natriuretic peptide, B, C and exogenous D-type, possess differing degrees of hemodynamic, neurohormonal, renal and cardiac effects

• Preservation of systemic blood pressures while causing significant reductions in central pressures

• Increases in urine sodium excretion and increased urinary volume while preserving glomerular filtration.

Non-steroidal mineralocorticoid receptor antagonists

• PF3882845 -greater blood pressure reduction and renal protection

• BR-4628 -dihydropyridine (DHP) structure

• specific MR antagonist without pronounced L-type calcium channel activity .

Aldosterone synthase inhibitors

• There is induction of aldosterone synthase (CYP11β2) or angiotensin II in the failing ventricle

• FAD286 - improved cardiac hemodynamic parameters, preventing progressive LV remodeling

• LCI699 - reduction in blood pressure

Multiple modes of

action• Dual ACE/NEP Inhibition – Vasopeptidase

Inhibitors• Omapatrilat, sampatrilat, fasidotrilat, MDL

100240, Z13752A, BMS 189921 and mixanpril• Dual NEP & ECE(endothelin converting enz.)

inhibitors• GGS34043, GGS34226, GGS26303, SLV306

• Triple enzyme inhibitors of ECE/NEP/ACE• GGS26670

• Dual dopamine D2-α2 agonist• Nolomirol

• Dopamine β-Hydroxylase inhibitor• Nepicastat

Rx of CCF

Dual ACE/NEP(Neutral Endopeptidase) Inhibition – Vasopeptidase Inhibitors• Omapatrilat, sampatrilat, fasidotrilat, MDL 100240, Z13752A,

BMS 189921 and mixanpril

• Superior to ACE inhibitors in increasing glomerular filtration rate and sodium excretion and decreasing PCWP

• Improvement in ventricular function in NYHA class II to IV heart failure.

• Drawback- Severe angioedema than ACEI

Dual Neutral Endopeptidase (NEP) and EndothelinConverting Enzyme (ECE) Inhibitors

• Endothelin converting enzyme helps in production of ET-1- a potent vasoconstrictor

• NEP degrades BNP and ANP- helps in natriuresis

• GGS 34226 and GGS 26303 are dual inhibitors of above enzymes

• Decreased preload, afterload and LV hypertrophy and increased cardiac output.

• Reducing right and left cardiac filling pressures

Triple Enzyme Inhibitors of ECE/NEP/ACE

• GGS 26670

• Improved LV function and reduced LV collagen accumulation better than either ACE alone or ECE-NEP inhibition

Dual Dopamine D2- a 2 Adrenoceptor agonist

• Nolomirole

• Inhibits catecholamine release from sympathetic nerve endings and also inhibits the release of TNF-a from cardiac tissue

• Significantly reduces hypertrophy and attenuates signs and symptoms

Dopamine ß - Hydroxylase Inhibitor

• DBH catalyses the conversion of dopamine (DA) to norepinephrine (NE) in sympathetic nerves

• Nepicastat (Phase II)- reduce norepinephrine synthesis.

• Attenuates ventricular remodeling and prevents systolic dysfunction

• Augments level of DA leading to renal vasodilation

Adenosine A1 receptor antagonists

• BG 9928, BG 9719

• Protects renal function and exerts additive natriuretic effects without excessive potassium loss

Carnitine Palmitoyl Transferase-1 (CPT-1) Inhibitors

• CPT-1 enzyme helps in metabolism of fatty acid which is a source of energy production in heart

• Etoxomir, Oxfenicine

• Convert energy production of heart from fatty acids to glucose

• Preserves cardiac function and prevents ventricular dilation, reduced PCWP. prevents ventricular remodeling.

Matrix Metalloproteinase (MMP) Inhibitors

• Enhanced expression of MMP triggers signaling cascade of cardiac remodeling

• Batimastat, ilomastat, marimastat and prinomastat, PG-53072

• Prevent ventricular dysfunction and delay heart failure progression

Immune modulator• CelacadeTM

• Prevents chronic inflammation and apoptotic cell death by activating physiological immune system’s IL -10 mediated anti-inflammatory process

• Celacade is a device-based outpatient procedure involving ex vivo exposure of 10ml autologous blood to heat, ultraviolet irradiation, controlled oxidative ozone therapy and subsequent intramuscular administration at monthly intervals.

• Improve quality of life in patients of NYHA class III or IV heart failure.

• Reduce the risk of death and hospitalization due to chronic heart failure

SummaryDrug/Molecule MOA Phase of Clinical Trial

Omecamtiv mecarbil Inotropic - Cardiac Myosite Activator II b

Istaroxime Na+/K+/ATPase inhibitor IISerelaxin Vasodilator IIIMYDICAR SERCA2a Activator III

Recombinant human NRG-1β2 Neuregulins III

Candoxatril, EcadotrilLCZ696AHU377

Angiotensin receptor and neprilysin inhibitorsAngiotensin receptorNeprilysin inhibitors II

PF3882845BR-4628 Non-steroidal mineralocorticoid receptor antagonists I

FAD286LCI699 Aldosterone synthase inhibitors I

Nepicastat Dopamine b -Hydroxylase Inhibitor II

BG 9928, BG 9719 Adenosine A1 receptor antagonists I

Etoxomir, Oxfenicine Carnitine Palmitoyl Transferase-1 (CPT-1) Inhibitors II

Batimastat, ilomastat, marimastat and prinomastat, PG-53072

Matrix Metalloproteinase (MMP) Inhibitors IIIx

Conclusion • The newer therapeutics may be potential candidates in future for

heart as increasing in understanding of pathophysiology of heart failure.

• Agents directly acting on remodeling process may even reverse current pathological condition of heart failure.

• Newer agents are seems to be beneficial over the older one in efficacy and safety wise eg: newer inotropes, RAAS antagonists…

• Gene therapy is also emerging as newer technique for HF seems to be promising in near future.

Three things for preventing heart diseases are – Eat less fried food, less butter and ghee. Second, exercise daily for around 45 minutes. And third, reduce stress in life

Take Home Message

THANK YOU

References • Harrison’s principles of internal medicine 18th ed.

• Essentials of medical Pharmacology; KD Tripathi; 7th edition

• Basic and Clinical Pharmacology; Kazung; 12th edition.

• Pharmacology & Therapeutics Volume 135, Issue 1, July 2012, Pages 1–17

• Novel Strategies for the Treatment of Heart Failure. RMMJ|www.rmmj.org.il.1 April 2012.Volume 3(2).0011

• Emerging Drug Therapies for Heart Failure.Ijpt. July 2006 | vol. 5 | no. 2 | 87-94